Hypovitaminosis C in patients treated with high-dose interleukin 2 and lymphokine-activated killer cells

Stuart L. Marcus, Daniel P. Petrylak, Janice P. Dutcher, Elisabeth M. Paietta, Niculae Ciobanu, Janice Strauman, Peter H. Wiernik, Seymour H. Hutner, Oscar Frank, Herman Baker

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Patients (n = 15) with metastatic malignant melanoma, hypernephroma, and colon carcinoma received a three-phase adoptive immunotherapy protocol: phase 1, 105 units (high-dose) interleukin-2 (IL-2) iv every 8 h or 1 mg/m2 continuous intravenous infusion; phase 2, 6.5 d rest + leukapheresis; phase 3, 4 d of high-dose IL-2 plus three infusions of autologous lymphokine-activated killer cells. Toxicities of treatment included fever, chills, tachycardia, hypotension, vomiting, diarrhea, and fluid retention. Patients entering the trial were not malnourished, and mean plasma ascorbic acid concentrations before therapy were normal (36.3 ± 14.2 μmol/L). Mean concentrations dropped by 80% after the first phase of treatment with high-dose IL-2 alone (to 7.4 ± 4.5 μmol/L). Mean plasma ascorbic acid concentrations remained severely depleted (between 4.5 and 7.4 μmol/L) throughout the remainder of the 15-d treatment. Ascorbic acid concentrations became undetectable (< 2.8 μmol/ L) in 12/15 patients during this time. Blood pantothenate and plasma vitamin E concentrations remained within normal limits in all patients tested throughout the phases of therapy.

Original languageEnglish (US)
JournalAmerican Journal of Clinical Nutrition
Volume54
Issue numberSUPPL. 6
StatePublished - Dec 1991
Externally publishedYes

Fingerprint

lymphokines
vitamin deficiencies
Lymphokine-Activated Killer Cells
interleukin-2
Interleukin-2
ascorbic acid
Ascorbic Acid
dosage
cells
therapeutics
hypotension
immunotherapy
Leukapheresis
Adoptive Immunotherapy
Therapeutics
vomiting
melanoma
Chills
fever
carcinoma

Keywords

  • Ascorbic acid
  • Chemotherapy
  • Immunotherapy
  • Interleukin-2
  • Lymphokine-activated killer cells

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Food Science

Cite this

Marcus, S. L., Petrylak, D. P., Dutcher, J. P., Paietta, E. M., Ciobanu, N., Strauman, J., ... Baker, H. (1991). Hypovitaminosis C in patients treated with high-dose interleukin 2 and lymphokine-activated killer cells. American Journal of Clinical Nutrition, 54(SUPPL. 6).

Hypovitaminosis C in patients treated with high-dose interleukin 2 and lymphokine-activated killer cells. / Marcus, Stuart L.; Petrylak, Daniel P.; Dutcher, Janice P.; Paietta, Elisabeth M.; Ciobanu, Niculae; Strauman, Janice; Wiernik, Peter H.; Hutner, Seymour H.; Frank, Oscar; Baker, Herman.

In: American Journal of Clinical Nutrition, Vol. 54, No. SUPPL. 6, 12.1991.

Research output: Contribution to journalArticle

Marcus, SL, Petrylak, DP, Dutcher, JP, Paietta, EM, Ciobanu, N, Strauman, J, Wiernik, PH, Hutner, SH, Frank, O & Baker, H 1991, 'Hypovitaminosis C in patients treated with high-dose interleukin 2 and lymphokine-activated killer cells', American Journal of Clinical Nutrition, vol. 54, no. SUPPL. 6.
Marcus, Stuart L. ; Petrylak, Daniel P. ; Dutcher, Janice P. ; Paietta, Elisabeth M. ; Ciobanu, Niculae ; Strauman, Janice ; Wiernik, Peter H. ; Hutner, Seymour H. ; Frank, Oscar ; Baker, Herman. / Hypovitaminosis C in patients treated with high-dose interleukin 2 and lymphokine-activated killer cells. In: American Journal of Clinical Nutrition. 1991 ; Vol. 54, No. SUPPL. 6.
@article{e55ad6e5d15d4b7388dae4bb19b085f8,
title = "Hypovitaminosis C in patients treated with high-dose interleukin 2 and lymphokine-activated killer cells",
abstract = "Patients (n = 15) with metastatic malignant melanoma, hypernephroma, and colon carcinoma received a three-phase adoptive immunotherapy protocol: phase 1, 105 units (high-dose) interleukin-2 (IL-2) iv every 8 h or 1 mg/m2 continuous intravenous infusion; phase 2, 6.5 d rest + leukapheresis; phase 3, 4 d of high-dose IL-2 plus three infusions of autologous lymphokine-activated killer cells. Toxicities of treatment included fever, chills, tachycardia, hypotension, vomiting, diarrhea, and fluid retention. Patients entering the trial were not malnourished, and mean plasma ascorbic acid concentrations before therapy were normal (36.3 ± 14.2 μmol/L). Mean concentrations dropped by 80{\%} after the first phase of treatment with high-dose IL-2 alone (to 7.4 ± 4.5 μmol/L). Mean plasma ascorbic acid concentrations remained severely depleted (between 4.5 and 7.4 μmol/L) throughout the remainder of the 15-d treatment. Ascorbic acid concentrations became undetectable (< 2.8 μmol/ L) in 12/15 patients during this time. Blood pantothenate and plasma vitamin E concentrations remained within normal limits in all patients tested throughout the phases of therapy.",
keywords = "Ascorbic acid, Chemotherapy, Immunotherapy, Interleukin-2, Lymphokine-activated killer cells",
author = "Marcus, {Stuart L.} and Petrylak, {Daniel P.} and Dutcher, {Janice P.} and Paietta, {Elisabeth M.} and Niculae Ciobanu and Janice Strauman and Wiernik, {Peter H.} and Hutner, {Seymour H.} and Oscar Frank and Herman Baker",
year = "1991",
month = "12",
language = "English (US)",
volume = "54",
journal = "American Journal of Clinical Nutrition",
issn = "0002-9165",
publisher = "American Society for Nutrition",
number = "SUPPL. 6",

}

TY - JOUR

T1 - Hypovitaminosis C in patients treated with high-dose interleukin 2 and lymphokine-activated killer cells

AU - Marcus, Stuart L.

AU - Petrylak, Daniel P.

AU - Dutcher, Janice P.

AU - Paietta, Elisabeth M.

AU - Ciobanu, Niculae

AU - Strauman, Janice

AU - Wiernik, Peter H.

AU - Hutner, Seymour H.

AU - Frank, Oscar

AU - Baker, Herman

PY - 1991/12

Y1 - 1991/12

N2 - Patients (n = 15) with metastatic malignant melanoma, hypernephroma, and colon carcinoma received a three-phase adoptive immunotherapy protocol: phase 1, 105 units (high-dose) interleukin-2 (IL-2) iv every 8 h or 1 mg/m2 continuous intravenous infusion; phase 2, 6.5 d rest + leukapheresis; phase 3, 4 d of high-dose IL-2 plus three infusions of autologous lymphokine-activated killer cells. Toxicities of treatment included fever, chills, tachycardia, hypotension, vomiting, diarrhea, and fluid retention. Patients entering the trial were not malnourished, and mean plasma ascorbic acid concentrations before therapy were normal (36.3 ± 14.2 μmol/L). Mean concentrations dropped by 80% after the first phase of treatment with high-dose IL-2 alone (to 7.4 ± 4.5 μmol/L). Mean plasma ascorbic acid concentrations remained severely depleted (between 4.5 and 7.4 μmol/L) throughout the remainder of the 15-d treatment. Ascorbic acid concentrations became undetectable (< 2.8 μmol/ L) in 12/15 patients during this time. Blood pantothenate and plasma vitamin E concentrations remained within normal limits in all patients tested throughout the phases of therapy.

AB - Patients (n = 15) with metastatic malignant melanoma, hypernephroma, and colon carcinoma received a three-phase adoptive immunotherapy protocol: phase 1, 105 units (high-dose) interleukin-2 (IL-2) iv every 8 h or 1 mg/m2 continuous intravenous infusion; phase 2, 6.5 d rest + leukapheresis; phase 3, 4 d of high-dose IL-2 plus three infusions of autologous lymphokine-activated killer cells. Toxicities of treatment included fever, chills, tachycardia, hypotension, vomiting, diarrhea, and fluid retention. Patients entering the trial were not malnourished, and mean plasma ascorbic acid concentrations before therapy were normal (36.3 ± 14.2 μmol/L). Mean concentrations dropped by 80% after the first phase of treatment with high-dose IL-2 alone (to 7.4 ± 4.5 μmol/L). Mean plasma ascorbic acid concentrations remained severely depleted (between 4.5 and 7.4 μmol/L) throughout the remainder of the 15-d treatment. Ascorbic acid concentrations became undetectable (< 2.8 μmol/ L) in 12/15 patients during this time. Blood pantothenate and plasma vitamin E concentrations remained within normal limits in all patients tested throughout the phases of therapy.

KW - Ascorbic acid

KW - Chemotherapy

KW - Immunotherapy

KW - Interleukin-2

KW - Lymphokine-activated killer cells

UR - http://www.scopus.com/inward/record.url?scp=0025885659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025885659&partnerID=8YFLogxK

M3 - Article

C2 - 1962585

AN - SCOPUS:0025885659

VL - 54

JO - American Journal of Clinical Nutrition

JF - American Journal of Clinical Nutrition

SN - 0002-9165

IS - SUPPL. 6

ER -